Inovio Pharmaceuticals (NASDAQ:INO) Share Price Crosses Above 200 Day Moving Average of $5.55

Inovio Pharmaceuticals, Inc. (NASDAQ:INOGet Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.55 and traded as high as $6.79. Inovio Pharmaceuticals shares last traded at $6.74, with a volume of 704,061 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on INO shares. StockNews.com lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Oppenheimer upgraded shares of Inovio Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $4.00 price objective for the company in a report on Thursday, January 25th. Finally, JMP Securities started coverage on shares of Inovio Pharmaceuticals in a report on Thursday, January 4th. They set a “market outperform” rating and a $12.00 price objective for the company.

View Our Latest Analysis on INO

Inovio Pharmaceuticals Stock Performance

The firm has a market cap of $153.27 million, a P/E ratio of -0.89 and a beta of 0.87. The firm’s fifty day moving average price is $6.37 and its 200 day moving average price is $5.55.

Inovio Pharmaceuticals (NASDAQ:INOGet Free Report) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.56) by $0.48. Inovio Pharmaceuticals had a negative net margin of 19,271.31% and a negative return on equity of 84.52%. The business had revenue of $0.39 million during the quarter, compared to analyst estimates of $0.18 million. As a group, analysts expect that Inovio Pharmaceuticals, Inc. will post -5.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Large investors have recently modified their holdings of the business. Graham Capital Management L.P. bought a new stake in shares of Inovio Pharmaceuticals in the 1st quarter valued at about $29,000. Allspring Global Investments Holdings LLC bought a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $30,000. Mariner LLC raised its stake in shares of Inovio Pharmaceuticals by 469.0% during the 3rd quarter. Mariner LLC now owns 76,093 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 62,719 shares in the last quarter. ExodusPoint Capital Management LP bought a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $34,000. Finally, Principal Financial Group Inc. raised its stake in shares of Inovio Pharmaceuticals by 11.4% during the 4th quarter. Principal Financial Group Inc. now owns 68,349 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 7,018 shares in the last quarter. Institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

(Get Free Report)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Further Reading

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.